FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808019712> ?p ?o ?g. }

• W2808019712 endingPage "24800" @default.
• W2808019712 startingPage "24787" @default.
• W2808019712 abstract "// Yekaterina Y. Zaytseva 1 , Piotr G. Rychahou 2, 3 , Anh-Thu Le 3 , Timothy L. Scott 4 , Robert M. Flight 4 , Ji Tae Kim 2 , Jennifer Harris 3 , Jinpeng Liu 2 , Chi Wang 2 , Andrew J. Morris 5 , Theru A. Sivakumaran 2 , Teresa Fan 4 , Hunter Moseley 4 , Tianyan Gao 2 , Eun Y. Lee 6 , Heidi L. Weiss 2 , Timothy S. Heuer 7 , George Kemble 7 and Mark Evers 2, 3 1 Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY, USA 2 Markey Cancer Center, University of Kentucky, Lexington, KY, USA 3 Department of Surgery, University of Kentucky, Lexington, KY, USA 4 RC-SIRM, University of Kentucky, Lexington, KY, USA 5 Cardiovascular Research, University of Kentucky, Lexington, KY, USA 6 Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY, USA 7 3-V Biosciences, Menlo Park, CA, USA Correspondence to: Yekaterina Y. Zaytseva, email: yyzayt2@email.uky.edu Keywords: colorectal cancer; FASN; lipogenesis; patient-derived xenografts; TVB-3664 Received: March 27, 2018      Accepted: April 26, 2018      Published: May 15, 2018 ABSTRACT Fatty Acid Synthase (FASN), a key enzyme of de novo lipogenesis, is upregulated in many cancers including colorectal cancer (CRC); increased FASN expression is associated with poor prognosis. Potent FASN inhibitors (TVBs) developed by 3-V Biosciences demonstrate anti-tumor activity in vitro and in vivo and a favorable tolerability profile in a Phase I clinical trial. However, CRC characteristics associated with responsiveness to FASN inhibition are not fully understood. We evaluated the effect of TVB-3664 on tumor growth in nine CRC patient-derived xenografts (PDXs) and investigated molecular and metabolic changes associated with CRC responsiveness to FASN inhibition. CRC cells and PDXs showed a wide range of sensitivity to FASN inhibition. TVB-3664 treatment showed significant response (reduced tumor volume) in 30% of cases. Anti-tumor effect of TVB-3664 was associated with a significant decrease in a pool of adenine nucleotides and alterations in lipid composition including a significant reduction in fatty acids and phospholipids and an increase in lactosylceramide and sphingomyelin in PDXs sensitive to FASN inhibition. Moreover, Akt, Erk1/2 and AMPK were major oncogenic pathways altered by TVBs. In summary, we demonstrated that novel TVB inhibitors show anti-tumor activity in CRC and this activity is associated with a decrease in activation of Akt and Erk1/2 oncogenic pathways and significant alteration of lipid composition of tumors. Further understanding of genetic and metabolic characteristics of tumors susceptible to FASN inhibition may enable patient selection and personalized medicine approaches in CRC." @default.
• W2808019712 created "2018-06-21" @default.
• W2808019712 creator A5009264842 @default.
• W2808019712 creator A5009997945 @default.
• W2808019712 creator A5015978857 @default.
• W2808019712 creator A5023436882 @default.
• W2808019712 creator A5023527864 @default.
• W2808019712 creator A5025018669 @default.
• W2808019712 creator A5031721512 @default.
• W2808019712 creator A5032605594 @default.
• W2808019712 creator A5036854706 @default.
• W2808019712 creator A5040212698 @default.
• W2808019712 creator A5058623652 @default.
• W2808019712 creator A5060684279 @default.
• W2808019712 creator A5063172780 @default.
• W2808019712 creator A5064191889 @default.
• W2808019712 creator A5066347342 @default.
• W2808019712 creator A5068753759 @default.
• W2808019712 creator A5078078599 @default.
• W2808019712 creator A5083222161 @default.
• W2808019712 creator A5084375387 @default.
• W2808019712 date "2018-05-15" @default.
• W2808019712 modified "2023-10-15" @default.
• W2808019712 title "Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer" @default.
• W2808019712 cites W127539000 @default.
• W2808019712 cites W1485543117 @default.
• W2808019712 cites W1499832207 @default.
• W2808019712 cites W1898639226 @default.
• W2808019712 cites W1964895626 @default.
• W2808019712 cites W1986234170 @default.
• W2808019712 cites W1989008846 @default.
• W2808019712 cites W1991952570 @default.
• W2808019712 cites W1992474783 @default.
• W2808019712 cites W1996566824 @default.
• W2808019712 cites W1997243908 @default.
• W2808019712 cites W2014428158 @default.
• W2808019712 cites W2021222670 @default.
• W2808019712 cites W2024074032 @default.
• W2808019712 cites W2029345191 @default.
• W2808019712 cites W2041987999 @default.
• W2808019712 cites W2043079400 @default.
• W2808019712 cites W2044406093 @default.
• W2808019712 cites W2069116752 @default.
• W2808019712 cites W2070360449 @default.
• W2808019712 cites W2070847866 @default.
• W2808019712 cites W2077732321 @default.
• W2808019712 cites W2083802683 @default.
• W2808019712 cites W2095246084 @default.
• W2808019712 cites W2095707070 @default.
• W2808019712 cites W2097365930 @default.
• W2808019712 cites W2098131661 @default.
• W2808019712 cites W2115152218 @default.
• W2808019712 cites W2118952409 @default.
• W2808019712 cites W2127903786 @default.
• W2808019712 cites W2134433047 @default.
• W2808019712 cites W2135805794 @default.
• W2808019712 cites W2137898985 @default.
• W2808019712 cites W2138110344 @default.
• W2808019712 cites W2153178365 @default.
• W2808019712 cites W2523687917 @default.
• W2808019712 cites W2554884877 @default.
• W2808019712 cites W2567412474 @default.
• W2808019712 cites W2572458874 @default.
• W2808019712 cites W2576882651 @default.
• W2808019712 cites W2583960272 @default.
• W2808019712 cites W2588603672 @default.
• W2808019712 doi "https://doi.org/10.18632/oncotarget.25361" @default.
• W2808019712 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5973868" @default.
• W2808019712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29872506" @default.
• W2808019712 hasPublicationYear "2018" @default.
• W2808019712 type Work @default.
• W2808019712 sameAs 2808019712 @default.
• W2808019712 citedByCount "79" @default.
• W2808019712 countsByYear W28080197122018 @default.
• W2808019712 countsByYear W28080197122019 @default.
• W2808019712 countsByYear W28080197122020 @default.
• W2808019712 countsByYear W28080197122021 @default.
• W2808019712 countsByYear W28080197122022 @default.
• W2808019712 countsByYear W28080197122023 @default.
• W2808019712 crossrefType "journal-article" @default.
• W2808019712 hasAuthorship W2808019712A5009264842 @default.
• W2808019712 hasAuthorship W2808019712A5009997945 @default.
• W2808019712 hasAuthorship W2808019712A5015978857 @default.
• W2808019712 hasAuthorship W2808019712A5023436882 @default.
• W2808019712 hasAuthorship W2808019712A5023527864 @default.
• W2808019712 hasAuthorship W2808019712A5025018669 @default.
• W2808019712 hasAuthorship W2808019712A5031721512 @default.
• W2808019712 hasAuthorship W2808019712A5032605594 @default.
• W2808019712 hasAuthorship W2808019712A5036854706 @default.
• W2808019712 hasAuthorship W2808019712A5040212698 @default.
• W2808019712 hasAuthorship W2808019712A5058623652 @default.
• W2808019712 hasAuthorship W2808019712A5060684279 @default.
• W2808019712 hasAuthorship W2808019712A5063172780 @default.
• W2808019712 hasAuthorship W2808019712A5064191889 @default.
• W2808019712 hasAuthorship W2808019712A5066347342 @default.
• W2808019712 hasAuthorship W2808019712A5068753759 @default.
• W2808019712 hasAuthorship W2808019712A5078078599 @default.
• W2808019712 hasAuthorship W2808019712A5083222161 @default.

• next